Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC).
Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the …

Hepatocellular carcinoma (HCC) is one of the most common and deadly human cancers.
The 5-year survival rate is very low. Unfortunately, there are few efficacious therapeutic …

Although sorafenib, an oral multikinase inhibitor, was approved as a treatment drug of
advance hepatocellular carcinoma (HCC), treatment efficacy still requires improvement …

Sorafenib is an orally administered multikinase inhibitor that exhibits anti-angiogenic and
anti-tumor activity. Sorafenib is also known to bind to protein (> 99.5%), suggesting protein …

Abstract Background Chronic infection with Hepatitis B virus (HBV) is the major risk factor of
Hepatocellular Carcinoma (HCC). This study is to explore the mechanism of sorafenib …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …

Sorafenib is the first and only po administrated drug currently approved to treat advanced
hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib …

OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a
single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for …

Background Intrahepatic cholangiocarcinoma (ICC) is rising in clinical importance due to the
increasing incidence worldwide, poor prognosis, and suboptimal response to therapies …

Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma
(HCC). Because most anticancer drugs act, at least in part, through the generation of …